RNTX

Rein Therapeutics, Inc.

0.87 USD

Last updated Sep 5, 12:12 UTC

Yesterday HIGH

$0.92

Yesterday LOW

$0.85

52w HIGH

$2.18

52w LOW

$0.69

EPS

-0.10

PE

-8.71

Next Earnings

Nov 13, 2026

Overview News Government Trades Fundamentals

Rein Therapeutics, Inc. stock is up 10.23% since 30 days ago. The next earnings date is Nov 13, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 9 September’s closed higher than August. 100% of analysts rate it a buy.

Benzinga Insights

Mon Jun 1, 2026

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Newsdesk

Mon Jun 1, 2026

HC Wainwright & Co. Maintains Buy on Rein Therapeutics, Lowers Price Target to $8

HC Wainwright & Co. analyst Brandon Folkes maintains Rein Therapeutics (NASDAQ:RNTX) with a Buy and lowers the price target from $10 to $8.
Benzinga Newsdesk

Fri May 15, 2026

Rein Therapeutics Q1 EPS $(0.19) Beats $(0.49) Estimate

Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.49) by 61.22 percent. This is a 24 percent increase over losses of $(0.25) per share from
Benzinga Newsdesk

Fri May 1, 2026

Rein Therapeutics shares are trading lower after the company announced the pricing of its $50 million offering of 50 million shares at $1.00 per share.
Benzinga Insights

Fri May 1, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session
Avi Kapoor

Fri May 1, 2026

Why Twilio Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Twilio Inc (NYSE: TWLO) reported strong Q1 results and raised future sales guidance above estimates, causing shares to jump 20.6% in pre-market trading. Other gainers include CUE, SST, AKAN, XXII, SDOT, TEAM, ISPC, and FIVN, while BAFN, RBLX, SKBL, and RNTX were among the losers.
Benzinga Newsdesk

Fri May 1, 2026

Reported Earlier, Rein Therapeutics Prices $50M Public Offering Of 50M Common Shares At $1.00 Per Share; Proceeds To Fund LTI-03 Phase 2 Trial
Benzinga Newsdesk

Wed Apr 29, 2026

Rein Therapeutics shares are trading lower. The company issued an update on its ongoing Phase 2 RENEW clinical trial evaluating LTI-03 for the treatment of idiopathic pulmonary fibrosis.
Benzinga Newsdesk

Wed Apr 29, 2026

Rein Therapeutics Enrolled 8 Patients In RENEW Trial

8 patients enrolled, with additional patients expected in the near termEnrollment initiated in March 2026, with patients being added on a regular basisClinical trial sites active in the United States, Australia,
Benzinga Newsdesk

Tue Apr 28, 2026

Rein Therapeutics Files Prospectus For 30M Share Offering At ~$1.66/Share

REIN THERAPEUTICS, INC.30,000,000 Shares of Common StockWe are selling 30,000,000 shares of our common stock at an assumed public offering price of $1.66 per share, the last reported sale price of our common stock